Cinepazide maleate (MD-67350), a maleate salt form of cinepazide, is a vasodilator.

Cinepazide exhibits strong chronotropic and inotropic effects. Intravenous administration of Cinepazide (1 mg/kg - 3 mg/kg) leads to an 8% increase in heart rate while reducing blood pressure by 4%. Cinepazide selectively enhances the functional activity of 5-HT neurons in the brain, although hypoxia inhibits its activity. Doses of Cinepazide (3 mg/kg - 30 mg/kg) administered intravenously transiently increase renal and femoral arterial blood flow, spinal and carotid blood flow, and cardiac output in anesthetized dogs while decreasing total peripheral resistance, exhibiting a concentration-dependent relationship with these effects. At 30 mg/kg, Cinepazide enhances the dilatory neural response of dog spinal blood vessels to intrathecal adenosine and adenylic acid. Cinepazide (1 mg - 10 mg) amplifies blood flow within spinal vessels in a dose-dependent manner, partially inhibited by pretreatment with intravenous aminophylline and unaffected by autonomic antagonists. Cinepazide is well absorbed, with over 60% excreted within 24 hours. Over five days, the excretion of Cinepazide through feces and urine is 58.3% and 36.7% in rats, 68.6% and 33.4% in dogs, and 38.1% and 61.3% in humans, respectively.